French Sleepiness Scale for Adolescents-8 items: A discriminant and diagnostic validation.


Journal

L'Encephale
ISSN: 0013-7006
Titre abrégé: Encephale
Pays: France
ID NLM: 7505643

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 22 02 2022
revised: 01 06 2022
accepted: 08 06 2022
medline: 28 3 2023
pubmed: 18 10 2022
entrez: 17 10 2022
Statut: ppublish

Résumé

The objective of the present study was to validate the Short Version of French Sleepiness Scale for Adolescents (FSSA) with eight items (FSSA8). A total of 384 adolescents, aged between 12 and 18 years, completed the FSSA8. These included 269 nonclinical adolescents and 115 adolescents admitted for overnight polysomnography and Multiple Sleep Latency Test (MSLT) because of suspected hypersomnia (85 patients with narcolepsy and 30 with other sleep disorders). Item response theory (IRT) assumptions were tested and psychometric properties were analysed. Matching on sex ratio and age was conducted to estimate concurrent criterion, diagnostic validity and cut-offs. IRT assumptions were validated confirming the one-dimensionality of the FSSA8. The latent continuum sleepiness for which the scale and its items are reliable encompassed most of the clinical subjects. FSSA8 is weakly correlated with MSLT. Distribution of scores for the nonclinical group and the clinical group differed significantly; the FSSA8 had very good screening validity in sleep disorders. The cut-off was seven points. The FSSA8 appeared to be more reliable for patients than for nonclinical participants and to be a good tool for screening excessive daytime sleepiness in sleep disorders.

Identifiants

pubmed: 36253180
pii: S0013-7006(22)00173-7
doi: 10.1016/j.encep.2022.06.004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109-116

Informations de copyright

Copyright © 2022 L'Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

M-P Gustin (MP)

Emerging Pathogens Laboratory-Fondation Mérieux, International Center for Infectiology Research (CIRI), Inserm U1111, CNRS UMR5308, ENS de Lyon, Lyon, France; Institute of Pharmaceutic and Biological Sciences, Public Health department, Biostatistics, University Claude-Bernard Lyon 1, Villeurbanne, France.

B Putois (B)

Faculty of Psychology, Swiss Distance Learning University, Brig 3900, Switzerland.

A Guyon (A)

Pediatric Sleep Unit, Hospital for Women Mothers & Children, Lyon 1 University, France; National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic hypersomnia and Kleine-Levin Syndrome (CNR narcolepsie-hypersomnie), France; Lyon Neuroscience Research Centre, CNRS UMR 5292-INSERM U1028-Lyon 1 University, Bron 69005, France.

M Lecendreux (M)

National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic hypersomnia and Kleine-Levin Syndrome (CNR narcolepsie-hypersomnie), France; Centre pédiatrique des pathologies du sommeil, Hôpital Robert Debré, Paris, France.

M-J Challamel (MJ)

Pediatric Sleep Unit, Hospital for Women Mothers & Children, Lyon 1 University, France.

S Plancoulaine (S)

Université de Paris Cité, Inserm, INRAE, CRESS, 75004 Paris, France.

S Bioulac-Rogier (S)

Service de Psychiatrie de l'enfant et l'adolescent, Hôpital Couple enfant, CHU Grenoble Alpes CHU CS 10217, 38046 Grenoble, France.

C Schroder (C)

University of Strasbourg; CNRS UPR 3212, Institute of Cellular and Integrative Neurosciences.

S Royant-Parola (S)

Réseau Morphée, Garches, France.

S Huguelet (S)

Faculty of Psychology, Swiss Distance Learning University, Brig 3900, Switzerland.

P Franco (P)

Pediatric Sleep Unit, Hospital for Women Mothers & Children, Lyon 1 University, France; National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic hypersomnia and Kleine-Levin Syndrome (CNR narcolepsie-hypersomnie), France; Lyon Neuroscience Research Centre, CNRS UMR 5292-INSERM U1028-Lyon 1 University, Bron 69005, France. Electronic address: patricia.franco@univ-lyon1.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH